A novel coronavirus (2019-nCoV) has been featured on every headline this past week as the WHO declares the outbreak a global public-health emergency. The 2019-nCoV causes illness ranging from the common cold to mores severe diseases such as Severe Acute Respiratory Syndrome (SARS), which can spread from person-to-person. The CDC believes that symptoms may appear in as few as 2 days or as long as 14 days after exposure. Common symptoms include a fever, cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe respiratory issues, kidney failure and even death.

The 2019-nCoV was first identified in Wuhan, China on December 31, 2019.  It quickly traveled around the world and the United States reported its first case on January 21, 2020. Since the break out (as of January 30th), over 7,800 people have been infected and 170 people have died, according to statistics. However, scientists believe that the real number is likely higher.

There is currently no vaccine to protect against the 2019-nCoV, nor any specific antiviral treatment. The best way to prevent the infection is to avoid being exposed to the virus. Government scientists in China, the United States and Australia, as well as those working at Johnson & Johnson, Moderna Therapeutics and Inovio Pharmaceuticals are all working quickly to develop a new vaccine. According to the New York Times, “The hunt began January 10th, when Chinese scientists posted the genetic make-up of the virus on a public database. The next morning, researchers at the National Institute of Health’s Vaccine Research Center in Maryland went to work. Within hours, they had pinpointed the parts of the genetic code that could be used to make a vaccine.”

Despite the quick response from several teams of scientist around the world, creating a vaccine for the 2019-nCoV can be a very long and expensive process.  The first step is to identify the natural or synthetic antigens that might help prevent it. Then scientist will study how it interacts on a cellular level. After they are able to identify that it will be safe and effective for humans, clinical trials begin for Phases 1 – 3 research.  After a successful Phase 3 trial (which could take up to several months or years), the manufacturer will submit for a license through the FDA, and it will be available for the general public. The only way to create a vaccine and determine if it is effective is to perform research studies at sites similar to Rochester Clinical Research, and provide the data to confirm that a vaccine is safe and effective. If you would like to help advance medicine and change lives and join a vaccine research study, please see below what we have available . Be sure to check back often, as we have new studies starting all the time.

Featured

Pneumococcal and Flu Vaccine Study

Rochester Clinical Research is currently seeking volunteers to participate in a pneumococcal and flu vaccine study. This study is for people who are 50 years or older and want to protect themselves against these two very contagious viruses before the Winter season. This study is approximately 7 months long and consists of 3 office visits and 4 telephone call check-ins. The purpose of the study is to test the safety and efficacy of the vaccine targeting the two viruses and different stains of the flu. If you qualify to participate, compensation will be provided for your time and travel.

View Trial Details
Ages 50+
Compensation* $250
Study Topics Vaccines

*Compensation for time and travel may be available to those who qualify.

Featured

Flu Vaccine Trial

Rochester Clinical Research is currently seeking volunteers who are 18 years and older for an Influenza vaccine study. The purpose of this study will be to evaluate the safety and immunogenicity of an mRNA vaccine to prevent influenza. Compensation for time and travel is available for around $630 to those who qualify.

View Trial Details
Ages 18+
Compensation* Around $630
Study Topics Vaccines

*Compensation for time and travel may be available to those who qualify.

Featured

Covid-19 Omicron Variant Vaccine Trial

Rochester Clinical Research is currently seeking volunteers over the age of 18 to participate in an omicron variant booster vaccine study. This paid research study is testing the efficacy and tolerability of an omicron variant-specific vaccine. The purpose of this vaccine is to provide extra protection against the highly contagious strain. The study is about 6 months long and requires 5 visits to the office.

View Trial Details
Ages 18+
Compensation* TBD (Waiting on contracts)
Study Topics Vaccines

*Compensation for time and travel may be available to those who qualify.

Featured

mRNA Flu Vaccine Study

Rochester Clinical Research is seeking volunteers who are 50 years and older to participate in an investigational mRNA flu vaccine study. The purpose of this study is to evaluate the effectiveness of using mRNA technology in an investigational flu vaccine and see if it protects against different variants. This is a phase 3 study and is about 12 months long with only one visit to our office.

View Trial Details
Ages 50+
Study Topics Vaccines

Pneumococcal Vaccine Study

Rochester Clinical Research is now seeking volunteers between the ages of 18 and 49 years old for a Pneumococcal vaccine study. This paid research study hopes to find a new pneumococcal vaccine that will potentially protect against strains not covered by the currently available vaccines. The study is approximately 6 months long and you can get up to $555 in study-related compensation.

View Trial Details
Ages 18 – 49
Compensation* $555
Study Topics Vaccines

*Compensation for time and travel may be available to those who qualify.

Chikungunya Vaccine Study

Rochester Clinical Research is participating in a study evaluating the immune response of a single dose of the Chikungunya vaccine in healthy adolescents between the ages of 12 and 17 years old. The study will last approximately 6 months with 7 visits to our office. Compensation is available for up to $650 for time and travel, for those who qualify.

View Trial Details
Ages 12 – 17
Compensation* $650
Study Topics Chikungunya Virus

*Compensation for time and travel may be available to those who qualify.

Dengue Fever Vaccine Study

Dengue fever is a virus that is carried by mosquitoes, usually in subtropical and tropical climates. Symptoms can range from either being mild or severe. The virus only lasts about a week, but if left untreated it could turn into severe symptoms. We are conducting a phase 2 study of a vaccine for people ages 18-50 years old to test the safety and efficiency of different doses given. It’s a one-year-long trial with 8 visits to the office.

View Trial Details
Ages 18 – 50
Compensation* $120 per visit
Study Topics Dengue Fever

*Compensation for time and travel may be available to those who qualify.

Chikungunya Vaccine Study

Chikungunya is a virus that can be spread through mosquito bites similar to other mosquito-spread illnesses like Zika, malaria, dengue, and West Nile Virus. RCR is conducting a study to test the effectiveness of a phase 3 vaccine to prevent Chikungunya in people who are 65 or older. The study will be 7 months long and consists of 5 office visits and 2 phone call appointments.

View Trial Details
Ages 50+
Compensation* $900
Study Topics Chikungunya Virus

*Compensation for time and travel may be available to those who qualify.

Featured

Flu Vaccine Study

Rochester Clinical Research is now seeking volunteers between the ages of 65 and 85 years old for an influenza vaccine study. The purpose of this research study is to evaluate the safety and effectiveness of an investigational influenza vaccine versus a currently approved influenza vaccine.

View Trial Details
Ages 65 – 85
Compensation* $625
Study Topics Flu Vaccine

*Compensation for time and travel may be available to those who qualify.

COVID booster plus Influenza Vaccine Study

Rochester Clinical Research is now enrolling volunteers between the ages of 18 and 75 years old for an investigational COVID vaccine booster plus flu vaccine study.

View Trial Details
Ages 18 – 75
Study Topics Vaccine

Migraine Relief Study

Rochester Clinical Research wants to help advance treatments for people who suffer from episodic migraines. We are conducting a study that is three months long and requires you to come in once a month to receive an injection. RCR is seeking healthy individuals between the ages of 18-65 who get 4-14 migraines a month to participate. This is a phase 4 study and Rochester Clinical research wants to help get this treatment FDA-approved so that people no longer have to let migraines slow down their day.

View Trial Details
Ages 18 – 65
Compensation* TBD (Waiting on contracts)
Study Topics Migraine

*Compensation for time and travel may be available to those who qualify.

COVID-19 Booster Vaccine

Rochester Clinical Research is seeking volunteers over the age of 18 for a COVID-19 vaccine study to potentially protect against specific variants of COVID-19.

View Trial Details
Ages 18 – 85
Compensation* $150 per visit
Study Topics Vaccine

*Compensation for time and travel may be available to those who qualify.

Featured

CMV Vaccine

Rochester Clinical Research is currently seeking born-female volunteers between the ages of 16 and 40 years old to participate in a CMV vaccine study. The purpose of this study is to find a safe and effective vaccine against Cytomegalovirus.

View Trial Details
Ages 16 – 40
Gender For female patients only
Study Topics Vaccine
Featured

RSV Vaccine Study

Rochester Clinical Research is currently seeking adults over the age of 64 years old for different RSV vaccine studies. Join an RSV vaccine study that is testing the efficacy of a vaccine that may prevent lower respiratory tract disease, which is associated with the RSV virus. The study will last about 24 to 30 months and consists up to 6 office visit and a monthly telephone appointment. Compensation may be up to $1,640 for time and travel to participate in the study. 

View Trial Details
Ages 65+
Compensation* $1,640
Study Topics Vaccine

*Compensation for time and travel may be available to those who qualify.